BEVERLY, MA--(Marketwire - April 12, 2010) - Cellceutix Corporation (
"This type of program is a great opportunity for companies like Cellceutix to get the word out about our important research efforts," said Mr. Evans. "We are going to keep looking for these chances to tell our story."
In animal studies, Kevetrin has been found to significantly delay tumor growth in multi-drug resistant lung, breast and colon cancer cell lines. On April 20, Cellceutix will be presenting a poster of important new data on Kevetrin at the American Association for Cancer Research (AACR) in Washington, DC. More information about these studies and the AACR presentation is available on the Cellceutix web site at www.cellceutix.com.
KM-391, Cellceutix's novel compound in development for the treatment of autism, was shown to improve several key parameters in an animal model of autism. Given the urgent medical need in this area, the Company is working as rapidly as possible to move KM-391 toward human studies. The pharmaceutical industry is only recently gearing up to develop drugs that address the primary conditions of autism. At Cellceutix we hope to stay ahead of the curve on autism research.
About Cellceutix
Cellceutix Corporation is a preclinical cancer and anti-inflammatory drug developer. Cellceutix owns the rights to eight drug compounds, including Kevetrin, which it is developing as a treatment for certain cancers, and KM-391, which it is developing for the treatment of autism. More information is available on the Cellceutix web site at www.cellceutix.com.
This Press Release contains forward-looking statements that are based on our current expectations, beliefs and assumptions about the industry and markets in which Cellceutix Corporation operates. Such forward-looking statements involve known and unknown risks, uncertainties, and other factors that may cause Cellceutix's actual results to be materially different from any future results expressed or implied by these statements. Actual results may differ materially from what is expressed in these statements, and no assurance can be given that Cellceutix can successfully implement its core business strategy and improve future earnings.
The factors that may cause Cellceutix's actual results to differ from its forward-looking statements include: Cellceutix's current critical need for additional cash to sustain existing operations and meet ongoing existing obligations and capital requirements; Cellceutix's ability to implement its new product development and commercialization, enter into clinical trials, expand the intellectual property portfolio, and receive regulatory approvals in a timely and cost-effective manner. All forward-looking statements are also expressly qualified in their entirety by the cautionary statements included in Cellceutix's SEC filings, including its quarterly reports on Form 10-Q and its annual report on Form 10-K.
Kevetrin and KM-391 have not been studied in humans at this time. The Company's positive results in animal studies do not necessarily guarantee success in humans, though they may form the basis for beginning Phase 1 trials.
Contact Information:
Contact:
Cellceutix Corp.
Leo Ehrlich
(978) 633-3623